HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana

AIDS

Volumn 27, Issue 12, 2013, Pages 1911-1920

  Shapiro, Roger L ^a,b,c   Kitch, Douglas ^b   Ogwu, Anthony ^c   Hughes, Michael D ^b   Lockman, Shahin ^b,c,d   Powis, Kathleen ^b,c,e   Souda, Sajini ^c   Moffat, Claire ^c   Moyo, Sikhulile ^c   McIntosh, Kenneth ^f   Van Widenfelt, Erik ^c   Zwerski, Sheryl ^g   Mazhani, Loeto ^h   Makhema, Joseph ^b,c   Essex, Max ^b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h UNIVERSITY OF BOTSWANA   (Botswana)

Author keywords

Africa; Antiretrovirals; Botswana; HIV; Infant survival; Maternal health; Mother to child HIV transmission

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; BOTSWANA; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CHILDBIRTH; CHILDHOOD MORTALITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GESTATION PERIOD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; MORBIDITY; MORTALITY; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WEANING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTSWANA; BREAST FEEDING; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84883402421     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32836158b0     Document Type: Article

References (29)

1. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-2294.
2. The Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
3. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52:406-416.
4. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-tochild HIV transmission through breastfeeding: the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8:e1001015.
5. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21 (Suppl 4):S65-S71.
6. Arendt V, Ndimubanzi P, Vyankandondera J, Ndayisaba G, Muganda J, Courteille O, et al. AMATA study: effectiveness of antiretroviral therapy in breastfeeding mothers to prevent postnatal vertical transmission in Rwanda. Fourth International AIDS Society Conference on HIV Treatment and Pathogenesis, Sydney, 22-25 July 2007. Abstract TuAX102.
7. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach: 2010 version. Geneva, Switzerland: WHO Press. http://whqlibdoc.who.int/publications/2010/9789241599818-eng.pdf.
8. Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet 2012; 379:2449-2458.
9. Heidari S, Mofenson LM, Hobbs CV, Cotton MF, Marlink R, Katabira E. Unresolved antiretroviral treatment management issues in HIV-infected children. J Acquir Immune Defic Syndr 2012; 59:161-169.
10. Omer SB. Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. AIDS 2011; 25:767-776.
11. Taha TE, Li Q, Hoover DR, Mipando L, Nkanaunena K, Thigpen MC, et al. Postexposure prophylaxis of breastfeeding HIVexposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr 2011; 57:319-325.
12. World Health Organization. WHO child growth standards and the identification of severe acute malnutrition in infants and children. Geneva, Switzerland: World Health Organization, 2006. http://www.who.int/nutrition/ publications/severemalnutrition/9789241598163-eng.pdf.
13. Matthews LT, Ribaudo HJ, Parekh NK, Chen JY, Binda K, Ogwu A, et al. Birth weight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for U.S.-born black infants. BMC Pediatr 2011; 11:115-122.
14. Botswana Ministry of Health. 2012 Botswana National HIV & AiDS treatment guidelines. Gaborone, Botswana: Ministry of Health.
15. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIVinfected adults in Haiti. N Engl J Med 2010; 363:257-265.
16. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
17. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDSfree HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
18. World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Geneva, Switzerland: WHO Press; 2012. http://whqlibdoc.who.int/hq/2012/WHO-HIV- 2012.6-eng.pdf.
19. Taha TE, Hoover DR, Chen S, Kumwenda NI, Mipando L, Nkanaunena K, et al. Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis 2011; 53:388-395.
20. Kuhn L, AldrovandiGM, Sinkala M, Kankasa C, Semrau K,Mwiya M, et al. Effects of early, abrupt weaning for HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130-141.
21. Rollins NC, Becquet R, Bland RM, Coutsoudis A, Coovadia HM, Newell ML. Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes. AIDS 2008; 22:2349-2357.
22. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. How many child deaths can we prevent this year? Lancet 2003; 362:65-71.
23. Kuhn L, Coovadia HM. Protecting infants of HIV-positive mothers in Malawi. Lancet 2012; 379:2405-2407.
24. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs. formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794-805.
25. Onyango-Makumbi C, Bagenda D, Mwatha A, Omer SB, Musoke P, Mmiro F, et al. Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: findings from two perinatal HIV prevention trials in Kampala, Uganda. J Acquir ImmuneDefic Syndr 2009, Sep 25. [Epub ahead of print]
26. Homsy J, Moore D, Barasa A, Were W, Likicho C, Waiswa B, et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2010; 53:28-35.
27. Kafulafula G, Hoover DR, Taha TE, Thigpen M, Li Q, Fowler MG, et al. Frequency of gastroenteritis and gastroenteritisassociated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53:6-13.
28. Lockman S, Smeaton L, Shapiro R, Thior I, Wester C, Makhema J, et al. Risk factors for and timing of infant mortality among HIV-exposed children: a randomized clinical trial in Botswana. 15th Conference on Retroviruses and Opportunistic Infections, Boston, 3-6 February 2008. Abstract 643.
29. Lockman S, Smeaton L, Shapiro R, Thior I, Wester C, Stevens L, et al., Mashi Study Team. Morbidity and mortality among infants born to HIV-infected mothers and randomized to breastfeeding versus formula-feeding in Botswana (Mashi Study). XVI International AIDS Conference, Toronto Canada, 13-18 August 2006. Abstract # TUPE0357.